Search Results

Alzamend Neuro, Inc. announced that the Nasdaq Hearings Panel granted Alzamend’s request to continue its listing on The Nasdaq Capital Market, subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550, which requires stockholder equity of at least $2.5 million, and satisfying all applicable requirements for continued listing on Nasdaq.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced that it closed upon the initial tranche of a private placement pursuant to the Securities Purchase Agreement with an institutional investor.

Alzamend Neuro, Inc. announced that it has terminated its “at-the-market” equity offering program relating to sales of common stock with Ascendiant Capital Markets, LLC, as sales agent.

Alzamend Neuro, Inc. today announced that Alzamend’s board of directors approved a one-for-fifteen reverse stock split of Alzamend’s common stock.